Jim Nelson, Monica Burton Yolly, Dr Brittany Lee discussed on On Point with Tom Ashbrook | Podcasts

Automatic TRANSCRIPT

We're also joined by Monica Burton Yolly. She's president of the American society for Clinical Oncology and a little earlier in the show. Dr Brittany Lee told us that we've never seen an explosion in terms of the number of possible treatments or therapies for cancer. As we are seeing right now, some two thousand different treatments in the pipeline. The. Research or clinical trial pipeline is a very exciting moment in cancer research, but Dr Bernard newly just before the break. We were also talking about how how individualized these therapies can be. So are we talking about, you know, slightly different therapies tailored for from person to person. Oh, perhaps you know. There is a whole emphasis right now on understanding the individual biology of every patient and being able to target that specifically that not only helps us develop treatments that work better. It helps us develop treatments that have fewer side effects. You know, many examples of this in its general direction. I believe we're heading in all of on college. I see. But Jim Nelson? Yeah, nearly was talking about the antigens that t- says, recognize we know now that many of those are generated by mutations that are part of the carcinogenic process itself. And so there's a big effort I'm I'm involved in some, but there's many, many groups trying to develop rapid ways of genome sequencing is that gets faster and cheaper to identify possible antigens, make them synthetically and then give them to patients along with with the I mean checkpoint block. With therapy, perhaps it much much lower doses and focus the response even more tightly on the cancer cells themselves. Well, Jim, Allison, and Monica Bertin newly. We've got a comment here this come in on our website and the person wants us to to make a point that I wanted to ask you about someone says, pla- come and calling themselves. Planes dealers says, I hope that in addition to the brilliant science involved, the show addresses the practical impact. In other words, the prices of these therapies. I mean the Jim, let me start with you. I mean, I'm seeing hundreds of thousands of dollars as a cost for some of these therapies is that is that right? Yes, just that's correct. And it's, it's, it's it's too. It's too high. It really is. I mean, I can understand some of it because in in development, aluminum, for example, it changed all the rules, the standard in points that used clinically for evaluating drugs that targeted cancer cells weren't useful anymore. So there are a lot of failed trials because he used the wrong in points and cetera, et cetera. So developmental costs were amazing as well. Probably the most expensive ever. I'm not sure, but still that's no, that's no reason to keep those prices up for they are now because they certainly don't reflect the cost of making the drug itself. So they've got to come down particularly as we get into combinations. And I all I can hope. I mean, that is outside my area, but I, I gotta hope that they they come down fast so that they can get to more patients newly. I mean, I know that you neither you or Jim or setting prices for drugs that are. That are coming out of clinical trial. I wanna knowledge that and also we've heard frequently over the many years and Jim just pointed to it that the development costs are. These drugs are very high because sometimes we're talking about decades of research, so that point also should be made. But on the other hand, I mean, both of you are in the world of cancer research. Are you concerned that as we have these potentially very game changing therapies coming out of the pipeline, but because their costs are so high, it could further sort of drive a wedge between the haves and have nots when it comes to availability and access to to healthcare in the United States. Well, that wedges there now Magna, you know, and and it's terrible, and it's something that concerns us every day. And you know, I think it's a broader discussion than just the cost of some very expensive Neutra transformative drugs. It's the cost of our entire healthcare system in the United States and how are we going to focus..

Coming up next